Technology ID
E-084-2009-0

Genetic Mutations Associated with Stuttering

Linked ID
TAB-1935
Inventors
Changsoo Kang (NIDCD)
Dennis Drayna (NIDCD)
Sheikh Riazuddin (University of Punjab)
Lead Inventors
Dennis Drayna (NIDCD)
Co-Inventors
Changsoo Kang (NIDCD)
Sheikh Riazuddin (University of Punjab)
Development Status
Early stage
Applications
Therapeutics
Therapeutic Areas
Reproductive Health
ICs
NIDCD
Commercial Applications
  • Genetic diagnosis of stuttering disorder
  • Therapeutics for stuttering disorder
NIH investigators, for the first time, identified specific mutations associated with stuttering. These mutations are located within the genes encoding three enzymes, Glc-NAc phosphotransferase catalytic subunit [GNPTAB], Glc-NAc phosphotransferase recognition subunit [GNPTG], and N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase [NAGPA]. Together these constitute the pathway that targets lysosomal enzymes to their proper location. This pathway is associated with lysosomal storage disorders, and thereby this discovery provides potential novel therapeutic targets for amelioration of stuttering. This discovery has the potential to facilitate DNA-based (micro-array) testing among individuals who stutter, as well as enzyme-replacement therapy and small-molecule chaperone therapy for treatment of stuttering. The mutations described in this invention may account for up to 5-10% of this disorder in individuals who stutter, estimated to represent 60,000-120,000 individuals in the United States.

Request More Info

Licensing Contact